Report: ESAs Largely Ineffective in Lower-Risk MDS
Patients with lower-risk myelodysplastic syndromes (LR-MDS) are unlikely to benefit from treatment with erythropoiesis-stimulating agents (ESAs), according to a new report. The study, which was published in the journal Clinical Lymphoma, Myeloma, and …